Bondrix 150 mg (Tablet)
1 tablet kit: ৳ 400.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Ibn sina pharmaceuticals ltd |
Title
- Bondrix 150 mg Tablet
Categories
- Medicine
- Osteoporosis Treatment
Description
- Monthly dosage for osteoporosis treatment
- Highly potent bisphosphonate
- Inhibition of bone resorption
- Prevents experimentally induced bone destruction
- Increases bone mass in young rats
- High affinity for hydroxyapatite in bone tissue
- Reduces bone resorption with no direct effect on bone formation
- Progressive net gain in bone mass in postmenopausal women
- Reduces levels of serum and urinary biochemical markers of bone turnover
- Decreases incidence of fractures
- Contraindicated in patients with known hypersensitivity to ibandronic acid or to any of the excipients
- Contraindicated in patients with uncorrected hypocalcemia
- Contraindicated in patients with esophageal abnormalities
- Contraindicated in patients unable to stand or sit upright for at least 60 minutes
- Main side effects: dyspepsia, nausea, diarrhea, abdominal pain, muscle aches, headaches, dizziness
- Not recommended during pregnancy or lactation
- Caution advised in patients with active upper gastrointestinal problems
Dosage & Administration
- One 150 mg film-coated tablet once a month
- Tablet should be taken on the same date each month
- Should be taken 60 minutes before the first food or drink of the day
- Swallowed whole with a full glass of plain water while sitting or standing upright
- Should not lie down for 60 minutes after taking
Interaction
- Calcium supplements, antacids, and some oral medications may interfere with absorption
- Pharmacokinetic interaction studies have shown absence of potential interactions with certain medications
- No dosage adjustment required when administered with H2-antagonists
Precautions & Warnings
- Hypocalcemia and other bone disturbances should be treated before therapy
- Caution for patients with active upper gastrointestinal problems
- Alert for signs or symptoms of possible esophageal reaction
- Use with caution during concomitant medication with NSAIDs
- Osteonecrosis of the jaw reported in patients treated with bisphosphonates
Use in Special Populations
- No dosage adjustment necessary for patients with mild or moderate renal impairment
- No dosage adjustment necessary for patients with hepatic impairment
- No dosage adjustment necessary for elderly patients
- Safety and efficacy not established in patients less than 18 years old
Overdose Effects
- Upper gastrointestinal adverse events may result from oral overdosage
- Milk or antacids should be given to bind the medicine
- Vomiting should not be induced
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Keep below 30°C temperature, away from light & moisture
- Keep out of the reach of children